{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-021262","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-06-22T13:02:23+00:00","discovered_at":"2026-06-22T13:03:00.327274+00:00","generated_at":"2026-06-22T13:03:30.969893+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Genprex receives Canadian patent allowance for REQORSA combo with PD-1/PD-L1 in lung cancer","bullets":["Canadian IPO issued Notice of Allowance for patent covering REQORSA with PD-1/PD-L1 antibodies for NSCLC and SCLC.","Patent expands existing IP portfolio for Acclaim-3 trial evaluating REQORSA combinations.","Canadian Cancer Society estimates 32,900 new lung cancer cases in 2026; 19,300 deaths."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-021262","json":"https://secwatch.observer/filing/0001437749-26-021262.json","markdown":"https://secwatch.observer/filing/0001437749-26-021262.md","text":"https://secwatch.observer/filing/0001437749-26-021262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926021262/0001437749-26-021262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926021262/gnpx20260619_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:03:30.969893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}